Markers for Acute Chemotherapy-Induced Cardiovascular Changes

Completed

• Conditions: Testicular cancer; Cancer

• Registration Number: ISRCTN54551960
• Lead Sponsor: niversity Medical Center Groningen (UMCG), Department of Internal Medicine: Division of Medical Oncology (The Netherlands)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2006-07-19
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Male
• Target Recruitment: 50

Inclusion Criteria

1. Patients with disseminated testicular cancer who will be treated with cisplatin based chemotherapy
2. Age 18-50 years at start of treatment
3. Written informed consent

Exclusion Criteria

1. Medical history of cardiovascular disease
2. Known renal disease or estimated glomerular filtration rate (GFR) <60 ml/min (using Cockcroft-Gault formula)

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The early effects of cisplatin-based chemotherapy on the number of circulating endothelial (progenitor) cells and the accumulation of AGEs, and their correlation with cardiovascular damage

Secondary Outcome Measures

Name	Time	Method
1. Evaluation of which treatment and patient-related factors (for example chemotherapy dose and presence of cardiovascular risk factors) predispose patients to cardiovascular damage during and after cisplatin-based chemotherapy<br>2. Determination of circulating apoptosis markers during and after cisplatin-based chemotherapy and their relation to tumor response and cardiovascular damage